Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.

Published byἩρακλείδης Αλεξανδρίδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid."— Presentation transcript:

1 Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission  Jia Chen, Lingyi Yang, Yi Fan, Yang Xu, Yue Han, Xiaowen Tang, Huiying Qiu, Chengcheng Fu, Miao Miao, Feng Chen, Depei Wu  Biology of Blood and Marrow Transplantation  Volume 24, Issue 4, Pages (April 2018) DOI: /j.bbmt Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Transplant outcome of the entire cohort. Comparison of (A) NRM, (B) CIR, (C) OS, and (D) RFS. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Transplant outcome of patients with favorable risk AML. Comparison of (A) NRM, (B) CIR, (C) OS, and (D) RFS. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Transplant outcome of patients with intermediate-risk AML. Comparison of (A) NRM, (B) CIR, (C) OS, and (D) RFS. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 OS patients suffering relapse after SCT. Comparison between (A) patients who underwent auto-SCT and haplo-SCT and (B) patients with low-risk and intermediate-risk AML. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid."

Similar presentations

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic.

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic.
Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics between Acute Myelogenous.

Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics between Acute Myelogenous.
Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Cytomegalovirus Glycoprotein B Genotype in Hematopoietic Stem Cell Transplant Patients from China  Xiaojin Wu, Ying Wang, Yang Xu, Depei Wu, Aining Sun,

Cytomegalovirus Glycoprotein B Genotype in Hematopoietic Stem Cell Transplant Patients from China  Xiaojin Wu, Ying Wang, Yang Xu, Depei Wu, Aining Sun,
KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.
Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia  Lan-Ping Xu, Zheng-Li Xu, Xiao-Hui Zhang, Huan.

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia  Lan-Ping Xu, Zheng-Li Xu, Xiao-Hui Zhang, Huan.
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Jacob M. Rowe  Biology of Blood and Marrow Transplantation 

Jacob M. Rowe  Biology of Blood and Marrow Transplantation 
Cytomegalovirus Glycoprotein B Genotype in Hematopoietic Stem Cell Transplant Patients from China  Xiaojin Wu, Ying Wang, Yang Xu, Depei Wu, Aining Sun,

Cytomegalovirus Glycoprotein B Genotype in Hematopoietic Stem Cell Transplant Patients from China  Xiaojin Wu, Ying Wang, Yang Xu, Depei Wu, Aining Sun,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Donor Selection for Killer Immunoglobulin-like Receptors B Haplotype of the Centromeric Motifs Can Improve the Outcome after HLA-Identical Sibling Hematopoietic.

Donor Selection for Killer Immunoglobulin-like Receptors B Haplotype of the Centromeric Motifs Can Improve the Outcome after HLA-Identical Sibling Hematopoietic.
Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for.

Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for.
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.
Betty T. Tran, Abigail Halperin, Jason W. Chien 

Betty T. Tran, Abigail Halperin, Jason W. Chien 
Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation  Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.

Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation  Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.
Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic.

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic.

Similar presentations

Ads by Google